Published in final edited form as:

Tetrahedron Lett. 2009 July 22; 50(29): 4265–4267. doi:10.1016/j.tetlet.2009.05.004.

Synthetic Studies Towards the Mitomycins: Construction of the Tetracyclic Core *via* a Reductive Aminocyclization Reaction

Daniel A. Gubler^a and Robert M. Williams^{a,b,*}

^a Department of Chemistry, Colorado State University, Fort Collins, Colorado 80523, USA

^b University of Colorado Cancer Center, Aurora, Colorado 80045, USA

Abstract

The tetracyclic core of the mitomycin family of natural products has been formed in one step from an acyclic precursor *via* a reductive aminocyclization reaction. Additionally, the 8-membered benzazocine can be prepared without the need for prior activation of the aniline. Construction of a mitomycin K analogue lacking the C9a methoxy moiety is also reported herein.

The mitomycin family of natural products (Figure 1) have been of interest to the scientific community since their isolation over 50 years ago.¹ Members of this family exhibit potent activity against a variety of cancer cell lines, and were found to be particularly active against solid tumors.² The mode of action of these compounds arises from their ability to form interstrand DNA-DNA³ as well as DNA-protein⁴ covalent cross-links. Mitomycin C (Figure 1) has been widely used clinically for over 40 years, and is still routinely employed today.⁵

These molecules present a significant synthetic challenge due to their densely functionalized nature, chemical lability as well as the difficulty in maintaining the vulnerable structural elements (i.e. aziridine, quinone, exo-methylene) as the synthesis unfolds. Despite the numerous reported synthetic efforts towards the mitomycins, only Kishi⁶, Fukuyama⁷, Danishefsky⁸, and Jimenez⁹ have been successful in completing total syntheses. It is important to note that all the syntheses mentioned above delivered racemic products and there exist no enantioselective total synthesis of any of the mitomycins reported to date.

Our research program has been focused on the development of an asymmetric total synthesis of the mitomycins which was a natural out-growth of our recently completed asymmetric total synthesis of (+)-FR900482¹⁰. These efforts are fueled in part by our interest in both the biosynthesis and mode of action of these compounds.¹¹ Herein we report efficient formation of the tetracyclic core of the mitomycins *via* a reductive aminocyclization reaction.

Previously, we reported the synthesis of benzazocines with the mitomycin substitution on the aromatic ring *via* an intramolecular Mitsunobu cyclization reaction.¹² We reported that prior activation of the aniline as the corresponding sulfonamide or carbamate was requisite for Mitsunobu cyclization to occur (Scheme 1). Through this method, benzazocines and

*Corresponding author. Tel.: +1-970-491-6747; fax: +1-970-491-3944; e-mail: rmw@lamar.colostate.edu.

Supporting Information. Complete experimental details and spectroscopic data for all new compounds.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

benzazocanes containing all the key elements of the mitomycins were efficiently obtained. However, conversion of these benzazocanes to the natural products proved difficult.

As part of our continuing efforts to access this family of natural products, a new strategy was developed. This strategy employed the use of benzyl ethers as protecting groups on the arene ring, as well as installation of the exocyclic methylene prior to cyclization (Scheme 2). The synthesis commenced by coupling of nitro arene **1**¹³ and aziridine aldehyde **2**¹⁴, followed by oxidation of the resultant alcohol (obtained as a 2:1 mixture of diastereomers *R* : *S*) to ketone **3**. Methylenation and removal of the PMB ether with DDQ proceeded in excellent yield over two steps to provide primary alcohol **4**. Conversion of alcohol **4** to the corresponding mesylate and reduction of the ketone under Luche conditions gave secondary alcohol **5** in high yield as a single diastereomer. Reduction of the nitro group using zinc dust did not provide the expected aniline **6**, but rather gave benzazocine **7**¹⁵ in near quantitative yield as the product of a reductive aminocyclization reaction. To the best of our knowledge, this is the first example of a cyclization reaction in this family of compounds that proceeds without the need for prior activation of the aniline.

Having found an efficient method for formation of benzazocine **7**, we were interested in examining the utility and scope of this transformation. Specifically, we investigated the possibility of forming the tetracyclic core of the mitomycins in one step from an acyclic precursor *via* this newly discovered reductive aminocyclization reaction. Accordingly, ketone **3** was transformed to bis-mesylate **8** in four straightforward steps consisting of PMB ether removal, mesylation, reduction of the ketone, and a second mesylation (Scheme 3). Treatment of bis-mesylate **8** under identical nitro reduction conditions furnished tetracyclic indoline **9** in 53% yield. Attempted conversion of indoline **9** to the mitomycins is now in progress.

With indoline **9** in hand, we decided to pursue the synthesis of mitomycin K using the same reaction, with prior installation of the C10 exocyclic olefin. Accordingly, mesylation of alcohol **5** under standard conditions provided the aminocyclization precursor bearing the exocyclic olefin (Scheme 4). Reductive aminocyclization conditions used previously did provide tetracycle **10** without any isomerization of the exocyclic olefin to the corresponding indole (mitosene) adduct.¹⁶ Treatment of tetracycle **10** under hydrogenation conditions gave quinone **11** in moderate yield. Quinone **11** comprises the core skeleton of mitomycin K, lacking only the C9a methoxy group. Installation of the requisite methoxy moiety may be accomplished by an allylic C-H activation strategy, and efforts in this vein are in progress.

In summary, benzazocines were synthesized in high yield by use of a reductive aminocyclization reaction without the need for prior activation of the aniline. The tetracyclic core of the mitomycins was also accomplished in a single step from an acyclic precursor using this methodology. This strategy was used in formation of the tetracyclic indoline compound **9**, as well as the core structure of mitomycin K bearing an exocyclic olefin (i.e. **10**).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by National Institutes of Health (CA51875). D.A.G is grateful to Eli Lilly for a graduate fellowship. Mass spectra were obtained on instruments supported by the NIH Shared Instrumentation Grant GM49631. Mr. Donald Dick is acknowledged for mass spectrometric data.

References

1. Hata T, Sano Y, Sugawara R, Matsumae A, Kanamori K, Shima T, Hoshi T. *J Antibiotics* 1956;9:141–146. [PubMed: 13385186]
2. Rajske SR, Williams RM. *Chem Rev* 1998;98:2723–2795. [PubMed: 11848977]
3. Iyer VN, Szybalski WA. *Proc Natl Acad Sci USA* 1963;50:355–361. [PubMed: 14060656]
4. Rajske SR, Rollins SB, Williams RM. *J Am Chem Soc* 1998;120:2192–2193.
5. Bradner WT. *Cancer Treat Rev* 2001;7:35–50. [PubMed: 11237776]
6. For a review on Kishi's synthesis of mitomycins A, B, and C see: Kishi Y. *J Nat Prod* 1979;42:549–568.
7. For a review of Fukuyama's synthesis of mitomycins A and C see: Fukuyama T, Yang L. *Studies Nat Prod Chem* 1993;13:433–471.
8. For a review on Danishefsky's synthetic efforts towards the mitomycins including the total synthesis of mitomycin K see: Danishefsky SJ, Schkeryantz JM. *Synlett* 1995:475–490.
9. Synthesis of Mitomycin K: Wang Z, Jimenez LS. *Tetrahedron Lett* 1996;37:6049–6052.
10. (a) Judd TC, Williams RM. *J Org Chem* 2004;69:2825–2830. [PubMed: 15074934] (b) Judd TC, Williams RM. *Angew Chem Int Ed Engl* 2002;41:4683–4685. [PubMed: 12481325]
11. For a recent report of ours towards the biosynthesis of the mitomycins see: Namiki H, Chamberland S, Gubler DA, Williams RM. *Org Lett* 2007;9:5341–5344. [PubMed: 18047354]
12. Ducept P, Gubler DA, Williams RM. *Heterocycles* 2006;67:597–619.
13. Prepared according to literature procedure: Kitahara Y, Nakahara S, Numata R, Kubo A. *Chem Pharm Bull* 1985;33:2122–2128.
14. Prepared according to literature procedure: Williams RM, Rollins SB, Judd TC. *Tetrahedron* 2000;56:521–532.
15. Ciufolini has developed a synthesis of a fully functionalized benzazocine as part of his strategy towards the mitomycins. Ciufolini MA II. *Farmaco* 2005;60:627–641. [PubMed: 16095596]
16. The general procedure for the reductive aminocyclization reaction is illustrated in the conversion of bis-mesylate (from alcohol 5) to tetracycle 10: To bis-mesylate (230 mg, 0.32 mmol, 1.0 equiv.) in 8.5 mL acetone/water (4:1) was added zinc dust (104 mg, 1.6 mmol, 5.0 equiv.), ammonium chloride (171 mg, 3.2 mmol, 10.0 equiv.), and then stirred at room temperature for 2 days. The reaction mixture was then concentrated, diluted (ethyl acetate), washed, (water and then brine), dried (sodium sulfate), filtered, and concentrated. Purification by column chromatography (3:1 hexanes/ethyl acetate) gave tetracycle 10 (87 mg, 55%) as a white foam. $[\alpha]_D^{20} +14.6$ ($c = 2.00$, CHCl_3); $^1\text{H NMR}$ (300 MHz, CDCl_3) δ TMS: 2.14 (3H, s), 3.28 (1H, dd, $J = 4.5, 2.1$ Hz), 3.36 (1H, dd, $J = 12.9, 2.1$ Hz), 3.42 (1H, dd, $J = 4.5, 2.7$ Hz), 3.65 (3H, s), 3.82 (3H, s), 4.21 (1H, d, $J = 12.9$ Hz), 4.58 (1H, m), 4.70 (1H, d, $J = 11.4$ Hz), 5.09 (1H, m), 5.28 (1H, d, $J = 2.1$ Hz), 5.92 (1H, d, $J = 2.4$ Hz), 7.57–7.35 (10H, m); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 10.0, 36.8, 44.4, 46.1, 51.1, 53.7, 60.9, 69.9, 72.2, 74.2, 120.1, 127.7, 127.9, 128.0, 128.1, 128.4, 128.5, 128.6, 128.7, 128.8, 128.9, 129.0, 137.7, 137.9, 138.6, 142.9, 145.2, 145.3, 145.5, 162.6; IR (neat) 3030, 2928, 1726, 1634, 1498, 1279 cm^{-1} ; HRMS (FAB) m/z calcd for $\text{C}_{30}\text{H}_{30}\text{N}_2\text{O}_5$ ($\text{M}+\text{H}$) $^+$ 498.21, found 498.21

Mitomycin A (MMA), R = OMe
Mitomycin C (MMC), R = NH₂

Mitomycin B, R = OMe
Mitomycin D, R = NH₂

Mitomycin K (MMK)

FR-900482

Figure 1.
The mitomycin family of natural products.

Scheme 1.

(a) $(\text{CH}_3)_2\text{NCON}=\text{NCON}(\text{CH}_3)_2$ (1.5 equiv), PBu_3 (1.8 equiv), toluene, rt, 6 h; 85%.

Scheme 2.

(a) 1 (2.0 equiv), 2 (1.0 equiv), ZnCl_2 (1.5 equiv), NaHMDS (2.0 equiv), DMF, -45°C , 2 h, 85%; (b) Dess-Martin (1.6 equiv), CH_2Cl_2 , rt, 2h, 98%; (c) formalin (112 equiv), LiOH (0.4 equiv), THF/water (20:3), rt, 20 h, 99%; (d) DDQ (1.3 equiv), CH_2Cl_2 /water (95:5), rt, 2 h, 92%; (e) MsCl (1.3 equiv), Et_3N (3.0 equiv), 0°C , 30 min, 85%; (f) $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$ (5.0 equiv), NaBH_4 (3.0 equiv), 0°C , 30 min, 92%; (g) Zn dust (5.0 equiv), NH_4Cl (10.0 equiv), acetone/water (4:1), rt, 3 h, 99%.

Scheme 3.

(a) DDQ (1.3 equiv), $\text{CH}_2\text{Cl}_2/\text{water}$ (95:5), rt, 2 h, 85%; (b) MsCl (1.5 equiv), Et_3N (3.0 equiv), $0\text{ }^\circ\text{C}$, 30 min, 53%; (c) $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$ (5.0 equiv), NaBH_4 (3.0 equiv), $0\text{ }^\circ\text{C}$, 30 min, 93%; (d) MsCl (1.5 equiv), Et_3N (3.0 equiv), $0\text{ }^\circ\text{C}$, 30 min, 75%; (e) Zn dust (5.0 equiv), NH_4Cl (10.0 equiv), acetone/water (4:1), rt, 3 h, 53%.

Scheme 4.

(a) MsCl (1.5 equiv), Et₃N (3.0 equiv), 0 °C, 30 min, 53%; (b) Zn dust (5.0 equiv), NH₄Cl (10.0 equiv), acetone/water (4:1), rt, 3 h, 55%; (c) 10 % Pd/C (120 wt. %), Et₃N (6.0 equiv), EtOAc, H₂, rt, 30 min, then O₂, 50%.